These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 35965282)
1. A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease. Li CH; Chen TF; Peng PL; Lin CH J Neurol; 2022 Dec; 269(12):6530-6543. PubMed ID: 35965282 [TBL] [Abstract][Full Text] [Related]
2. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease. Chen CH; Lee BC; Lin CH J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681 [TBL] [Abstract][Full Text] [Related]
3. Integrated Clinical Features with Plasma and Multi-modal Neuroimaging Biomarkers to Diagnose Mild Cognitive Impairment in Early Drug-Naive Parkinson's Disease. Wang Y; Ning H; Ren J; Pan C; Yu M; Xue C; Wang X; Zhou G; Chen Y; Liu W ACS Chem Neurosci; 2022 Dec; 13(23):3523-3533. PubMed ID: 36417458 [TBL] [Abstract][Full Text] [Related]
4. Diffusion and structural MRI as potential biomarkers in people with Parkinson's disease and cognitive impairment. Huang CC; Chen PH; Tsai CC; Chiang HF; Hsieh CC; Chen TL; Liao WH; Chen YL; Wang JJ Eur Radiol; 2024 Jan; 34(1):126-135. PubMed ID: 37572194 [TBL] [Abstract][Full Text] [Related]
5. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300 [TBL] [Abstract][Full Text] [Related]
6. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633 [TBL] [Abstract][Full Text] [Related]
7. Plasma α-synuclein predicts cognitive decline in Parkinson's disease. Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072 [TBL] [Abstract][Full Text] [Related]
8. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease. Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583 [TBL] [Abstract][Full Text] [Related]
11. Plasma total tau predicts executive dysfunction in Parkinson's disease. Lin WT; Shaw JS; Cheng FY; Chen PH Acta Neurol Scand; 2022 Jan; 145(1):30-37. PubMed ID: 34398474 [TBL] [Abstract][Full Text] [Related]
12. Association Between White Matter Connectivity and Early Dementia in Patients With Parkinson Disease. Chung SJ; Kim YJ; Jung JH; Lee HS; Ye BS; Sohn YH; Jeong Y; Lee PH Neurology; 2022 May; 98(18):e1846-e1856. PubMed ID: 35190467 [TBL] [Abstract][Full Text] [Related]
13. Cortical atrophy is associated with cognitive impairment in Parkinson's disease: a combined analysis of cortical thickness and functional connectivity. Zhu Y; Yang B; Zhou C; Gao C; Hu Y; Yin WF; Yin K; Zhu Y; Jiang G; Ren H; Pang A; Yang X Brain Imaging Behav; 2022 Dec; 16(6):2586-2600. PubMed ID: 36044168 [TBL] [Abstract][Full Text] [Related]
14. Analysis among cognitive profiles and gray matter volume in newly diagnosed Parkinson's disease with mild cognitive impairment. Noh SW; Han YH; Mun CW; Chung EJ; Kim EG; Ji KH; Seo JH; Kim SJ J Neurol Sci; 2014 Dec; 347(1-2):210-3. PubMed ID: 25451006 [TBL] [Abstract][Full Text] [Related]
15. Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease. Liang K; Li X; Guo Q; Ma J; Yang H; Fan Y; Yang D; Shi X; She Z; Qi X; Gu Q; Chen S; Zheng J; Li D Neurobiol Dis; 2024 Jan; 190():106379. PubMed ID: 38104911 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment. Samat NA; Abdul Murad NA; Mohamad K; Abdul Razak MR; Mohamed Ibrahim N Front Neurosci; 2017; 11():712. PubMed ID: 29326545 [No Abstract] [Full Text] [Related]
17. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. Pagonabarraga J; Corcuera-Solano I; Vives-Gilabert Y; Llebaria G; García-Sánchez C; Pascual-Sedano B; Delfino M; Kulisevsky J; Gómez-Ansón B PLoS One; 2013; 8(1):e54980. PubMed ID: 23359616 [TBL] [Abstract][Full Text] [Related]
18. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology. Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894 [TBL] [Abstract][Full Text] [Related]
19. Neuroimaging outcomes associated with mild cognitive impairment subtypes in Parkinson's disease: A systematic review. Devignes Q; Lopes R; Dujardin K Parkinsonism Relat Disord; 2022 Feb; 95():122-137. PubMed ID: 35249807 [TBL] [Abstract][Full Text] [Related]
20. Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease. Xu Y; Yang J; Hu X; Shang H J Neurol; 2016 Jun; 263(6):1178-87. PubMed ID: 27113603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]